Skip to content
DraconiticResearch
Search Sources API
197,761 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BYCell death & disease

Cell death-based treatment of ovarian cancer.

  • Aygun R Mamedova1,2
  • Gelina S Kopeina1
  • Boris Zhivotovsky3,4,5
  • Larisa V Smolyaninova6,7
7 affiliations
  1. 1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
  2. 2Faculty of Medicine, MV Lomonosov Moscow State University, Moscow, Russia.
  3. 3Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. [email protected].
  4. 4Faculty of Medicine, MV Lomonosov Moscow State University, Moscow, Russia. [email protected].
  5. 5Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden. [email protected].
  6. 6Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. [email protected].
  7. 7Faculty of Medicine, MV Lomonosov Moscow State University, Moscow, Russia. [email protected].
Read full textPDFDOICite

Abstract

Ovarian cancer (OC) is the seventh most prevalent type of cancer in women and one of the most lethal gynecological malignancies, due to the poor prognosis (with a 5-year survival rate of about 50%), the lack of specific clinical symptoms, the absence of effective screening, and the fact that the tumor grows without obvious signs. These factors complicate early detection, when clinical intervention is most effective, leading to late diagnosis. Standard treatment for OC includes cytoreductive surgery followed by platinum-based chemotherapy (PBC) with carboplatin and paclitaxel or their analogs. Conversely, despite the initial positive response to chemotherapy, many patients experience disease recurrence and develop chemotherapy resistance, which makes long-term treatment challenging and often results in fatal outcomes. Here, we focus on therapeutic strategies that overcome this resistance by precisely targeting pathways of programmed cell death (PCD), thereby opening new avenues for treatment. The potential of using PCD in OC treatment is being considered, focusing on key regulatory mechanisms: triggering intrinsic and/or extrinsic apoptosis; the complex role of autophagy in both promoting survival and inducing cell death; the emerging relevance of ferroptosis activation through inhibition of GPX4 or blockade of Xc- system; and the potential of using necroptosis and pyroptosis as immunogenic PCD modalities that can activate an immune response against the tumor. The use of these different PCD pathways offers opportunities to sensitize resistant tumors and improve patient outcomes.

Related

  1. Ceranib-2 potentiates cisplatin activity under an experimental in vitro hipec-like model by inducing integrated stress and cell death pathways in ovarian cancer
    Celal Cengiz, Canan Vejselova Sezer, Bahri Gür +2
    Scientific ReportsPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossref
  2. Paraptosis, a new type of cell death that can be applied to cancer treatment.
    Xudong Wang, Jiaxing Ma, Bowen Tan +5
    Frontiers in oncologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCCrossref
  3. Infrared Treatment Alters the Chemical Profile and In Vitro Bioactivity of Jojoba Oil: Antimicrobial, Biofilm Formation Inhibition and Ovarian Cancer Cell Responses
    Husam Qanash, Aisha M. H. Al-Rajhi, Abdulrahman S. Bazaid +7
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  4. Cell death pathways and targeting therapeutics in cancer therapy
    Bo Zhan, Hai-liang Zhang, Ying Xiao +6
    Acta Pharmacologica SinicaPeer-reviewedLicence not statedFull text2 citedMolecular biology & gene regulationPMC
  5. Inflammatory cell death in cancer: linking pyroptosis, necroptosis, ferroptosis, PANoptosis, and antitumor immunity
    Shanshan Li, Zihan Zhou, Peng Li +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@article{mamedova2026cell,
  title = {{Cell death-based treatment of ovarian cancer.}},
  author = {Aygun R Mamedova and Gelina S Kopeina and Boris Zhivotovsky and Larisa V Smolyaninova},
  journal = {Cell death \& disease},
  year = {2026},
  month = aug,
  doi = {10.1038/s41419-026-09133-x},
  url = {https://europepmc.org/article/MED/42957658},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Cell death-based treatment of ovarian cancer.
AU  - Aygun R Mamedova
AU  - Gelina S Kopeina
AU  - Boris Zhivotovsky
AU  - Larisa V Smolyaninova
PY  - 2026
DA  - 2026/08/03
JO  - Cell death & disease
DO  - 10.1038/s41419-026-09133-x
UR  - https://europepmc.org/article/MED/42957658
AB  - Ovarian cancer (OC) is the seventh most prevalent type of cancer in women and one of the most lethal gynecological malignancies, due to the poor prognosis (with a 5-year survival rate of about 50%), the lack of specific clinical symptoms, the absence of effective screening, and the fact that the tumor grows without obvious signs. These factors complicate early detection, when clinical intervention is most effective, leading to late diagnosis. Standard treatment for OC includes cytoreductive surgery followed by platinum-based chemotherapy (PBC) with carboplatin and paclitaxel or their analogs. Conversely, despite the initial positive response to chemotherapy, many patients experience disease recurrence and develop chemotherapy resistance, which makes long-term treatment challenging and often results in fatal outcomes. Here, we focus on therapeutic strategies that overcome this resistance by precisely targeting pathways of programmed cell death (PCD), thereby opening new avenues for treatment. The potential of using PCD in OC treatment is being considered, focusing on key regulatory mechanisms: triggering intrinsic and/or extrinsic apoptosis; the complex role of autophagy in both promoting survival and inducing cell death; the emerging relevance of ferroptosis activation through inhibition of GPX4 or blockade of Xc- system; and the potential of using necroptosis and pyroptosis as immunogenic PCD modalities that can activate an immune response against the tumor. The use of these different PCD pathways offers opportunities to sensitize resistant tumors and improve patient outcomes.
SN  - 2041-4889
ER  -